Skip to main content


Cancer Control Program

Areas of Interest:

  • Hepatocellular carcinoma
  • Metabolic-Dysfunction Associated Steatotic Liver Disease
  • Alcohol-associated Liver Disease
  • Non-invasive biomarkers
  • Genetics
  • Epidemiology
  • Clinical trial design
  • Integrated OMICS

Active or most recent cancer-related grant (s):

  • U01DK130190 “San Diego Cirrhosis Clinical Research Network”
  • U01DK061734 “Clinical Research on Metabolic-Dysfunction Associated Steatotic Liver Disease
  • U01AA029019 “Novel IL-23 inhibitor for the treatment of alcohol-associated liver disease”
  • R01DK124318 “Non-invasive screening of diabetics for advanced fibrosis due to MASLD”
  • P01HL147835 “Role of liver fat and fibrosis in human CVD risk phenotypes.” R01DK121378 “Ancillary Studies of MASLD and MASH in HIV infected Adults”
  • P30DK120515 “San Diego Digestive Disease Research Center Human Translational Core”

Most important recent cancer-related publications:

  • Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R.Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022
  • Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022
  • Strnad P, Mandorfer M, Choudhury G, Griffiths W, Trautwein C, Loomba R, Schluep T, Chang T, Yi M, Given BD, Hamilton JC, San Martin J, Teckman JH. Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency. N Engl J Med. 2022